Aidigong Maternal & Child Health Limited (Stock code: 286) released a new announcement detailing its progress toward trading resumption, ongoing business operations, and recent litigation developments. The announcement highlights that the group continues to operate its core businesses despite the ongoing suspension of share trading.

The announcement explains that the 2024 annual results remain under review. The company reports continued challenges in obtaining the necessary financial information from Shenzhen Aidigong and its subsidiaries, which has delayed completion of the annual audit. The timing for publication of the 2024 annual results and corresponding annual report will be agreed upon with the auditors at a later date.

The company reiterates its commitment to resuming share trading. It notes ongoing difficulty in finalizing the scope of an independent forensic investigation related to Shenzhen Aidigong, as well as a review of internal controls. Additional steps include reviewing board composition to ensure compliance with applicable listing rules.

Regarding litigation, the announcement provides an update on the court proceedings in Shenzhen. Guangdong Wanjia, a party to the related lawsuit, received a summons regarding the validity of a previous resolution and a change of legal representative in Shenzhen Aidigong. The court hearing is scheduled for 23 March 2026, and the outcome remains uncertain.

According to the announcement, trading in the company’s shares has been suspended since 21 February 2025 and will remain on hold until further notice. The company advises shareholders and potential investors to exercise caution in dealing with its securities, pending further updates on the resumption guidance.